Joe A. Wrennall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joe A. Wrennall has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Livraghi-Butrico
University of North Carolina at Chapel Hill
1 shared publication - Athanasios Fysikopoulos
Justus-Liebig University, Excellence Cluster Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany
1 shared publication - Charles D. Bengtson
Division of Pulmonary Critical Care and Sleep Medicine, University of Kansas Medical Center , Kansas City, Kansas
1 shared publication Christine Rothe
Pieris Pharmaceuticals GmbH
1 shared publicationCornelia Wurzenberger
Pieris Pharmaceuticals GmbH
1 shared publicationEva-Maria Hansbauer
Pieris Pharmaceuticals GmbH
1 shared publication
Latest Publications
- Open Access
- 27 August 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (6) , 1173-1183
Neutrophil store-operated Ca2+ entry: A correctable biomarker of cystic fibrosis lung disease progression
- 27 August 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (6) , 1173-1183
Open AccessNeutrophil store-operated Ca2+ entry: A correctable biomarker of cystic fibrosis lung disease progression
- Open Access
- 1 January 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 328 (1) , L75-L92
Pulmonary-delivered Anticalin Jagged-1 antagonists reduce experimental airway mucus hyperproduction and obstruction
Airway mucus drives severity and mortality in diverse chronic lung diseases. The Jagged-1/Notch pathway controls the balance of ciliated versus mucous cells, but targeting the pathway systemically carries the risk of side effects. Here we developed novel, Anticalin-derived, pulmonary-delivered Jagged-1 antagonists, to inhibit airway mucus hyperproduction and obstruction in chronic lung diseases. Our preclinical data demonstrate the effectiveness of these antagonists in diminishing secretory cell and mucus levels and alleviating hallmarks of mucus obstruction.
- 1 January 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 328 (1) , L75-L92
Open AccessPulmonary-delivered Anticalin Jagged-1 antagonists reduce experimental airway mucus hyperproduction and obstruction
Airway mucus drives severity and mortality in diverse chronic lung diseases. The Jagged-1/Notch pathway controls the balance of ciliated versus mucous cells, but targeting the pathway systemically carries the risk of side effects. Here we developed novel, Anticalin-derived, pulmonary-delivered Jagged-1 antagonists, to inhibit airway mucus hyperproduction and obstruction in chronic lung diseases. Our preclinical data demonstrate the effectiveness of these antagonists in diminishing secretory cell and mucus levels and alleviating hallmarks of mucus obstruction.